Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Zhonghua yi xue za zhi 2010-Nov

[Clinical efficacy of a short-term regimen of Cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia].

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Le lien est enregistré dans le presse-papiers
Peng Zhang
Zhi-Jin Wu
Yong Yang
Xiao-Dong Zhang

Mots clés

Abstrait

OBJECTIVE

To evaluate the clinical efficacy of Cardura XL (doxazosin mesylate controlled release tablets) on lower urinary tract symptoms, IPSS (international prognostic scoring system) and short-term QOL (quality of life) (3 months) in the treatment of benign prostatic hyperplasia (BPH).

METHODS

From July 2008 to February 2009, 80 male BPH patients with a mean age of 70.5 years old (range: 62-82) were prospectively recruited to receive a daily dose of Cardura XL 4 mg for 3 months. Clinical parameters of IPSS QOL, Qmax (maximum flow rate), residual urine, blood pressure and heart rate were recorded before and 3 months after treatment. Paired t test was performed on the corresponding data. And therapeutic efficacy and side effects were analyzed according to the statistical results.

RESULTS

All 80 patients finished a 3-month medical regimen. Between pre-treatment and 3 months after medication, paired t test was performed on the corresponding data of maximum flow rate (Qmax), residual urine, IPSS, QOL, blood pressure and heart rate. Significant differences were observed in all corresponding data (P < 0.001) except heart rate (P = 0.685). Furthermore analyses were performed on the corresponding IPSS and QOL between one month and 3 months after treatment. Significant improvement was also observed in IPSS and QOL after a longer medication (P < 0.001). Transient side effects were observed in 16 patients (20%): headache (n = 8, 10%), fatigue (n = 4, 5%) and dizziness (n = 4, 5%). No patient withdrew from the study.

CONCLUSIONS

Cardura XL, at a daily dose of 4 mg daily for 3 months, is a safe and effective regimen in BPH patients. Significant improvement is observed for lower urinary tract symptoms, IPSS and QOL. A longer medication may lead to further improvement of IPSS and QOL. After dosing, both systolic and diastolic blood pressures fall down significantly. No significant effect on heart rate is found. And most patients have an excellent tolerance.

Rejoignez notre
page facebook

La base de données d'herbes médicinales la plus complète soutenue par la science

  • Fonctionne en 55 langues
  • Cures à base de plantes soutenues par la science
  • Reconnaissance des herbes par image
  • Carte GPS interactive - étiquetez les herbes sur place (à venir)
  • Lisez les publications scientifiques liées à votre recherche
  • Rechercher les herbes médicinales par leurs effets
  • Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées

Google Play badgeApp Store badge